NCT02745535View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

PHASE2CompletedINTERVENTIONAL

Enrollment

77

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 24, 2018

Study Completion Date

October 24, 2018

Conditions

Chronic Hepatitis C

Interventions

DRUG

Sofosbuvir/Velpatasvir/Voxilaprevir

Trial Locations (1)

21201

Institute of Human Virology, Baltimore

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Unity Health Care, Inc.

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

University of Maryland, Baltimore

OTHER